Navigation Links
EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries

WATERTOWN, Mass., April 1, /PRNewswire/ -- EnVivo Pharmaceuticals today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries.

EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognition enhancement in patients with Alzheimer's disease and Schizophrenia. EnVivo recently reported positive results of its clinical bio-marker study in Schizophrenia patients in which EVP-6124 showed a significant improvement in several sensory and cognition markers. These evoked response biomarkers correlate with the degree of impairment of awareness, cognition and judgment, as well as the overall clinical condition of patients with Schizophrenia. EnVivo's clinical study in Alzheimer's patients, both naive and already on acetylcholine esterase inhibitors, is ongoing.

"MTPC is one of Japan's largest and most respected pharmaceutical companies," said Kees Been, EnVivo's chief executive officer, "and we believe that its experience in CNS-related diseases in general and its commitment in Alzheimer's disease and Schizophrenia makes MTPC an ideal partner for EVP-6124 in the Japan and Asia markets. With the strength of EnVivo's clinical data and MTPC's additional financial and development resources, we hope this partnership will accelerate the availability of a new and valuable therapy to Alzheimer's and Schizophrenia patients in the MTPC territory."

Collaboration arrangements

Under the terms of the agreement, MTPC has obtained exclusive rights to develop and commercialize EnVivo's alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan, Korea, Taiwan, Indonesia and several other Asian markets. MTPC plans to initiate Phase I clinical trials within 2010. EnVivo will receive an initial license payment and is eligible for clinical and regulatory milestones, as well as several commercial milestones. EnVivo also will receive royalties on sales of EVP-6124 in the MTPC territory.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Huntington's disease, cognition and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and is being tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) for cognition in Alzheimer's disease, and several preclinical programs such as a Gamma Secretase Modulator and a PDE10 inhibitor. For more information about EnVivo, visit

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation is a research-driven global biopharmaceutical leader based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on cardiovascular and metabolic disorders, and immune and inflammatory diseases as well as central nervous system-related disorders. In particular, MTPC strategically focuses on drug discovery in the field of diabetes including a broad range of clinical states from metabolic risks (obesity/dyslipidemia) to complications (renal dysfunction/dialysis) and stroke including the total range of disease phases such as acute phase, convalescence and maintenance. MTPC is currently developing two Phase III clinical candidates in the U.S. and EU: MCI-196 for hyperphosphatemia and MP-146 for CKD. For more information, please visit the web site at

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mitsubishi Electric Automation Showcases Advanced Material Handling Solutions at the North American Material Handling Show (NA 08)
2. Scientists Spot Brains Free Will Center
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
10. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
11. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology: